Anagrelide

Platelet-reducing Agent — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Key facts

Anagrelide is an ofp drug in the Platelet-reducing Agent class catalogued in DrugCentral. It was first approved by the FDA in 1997. Its mechanism of action is classified as Phosphodiesterase 3 Inhibitors. DrugCentral lists 2 molecular targets, including PDE3A and PDE2A. Recorded indications include Essential thrombocythemia and Thrombocytosis in Myeloproliferative Disease.

• Approval status: ofp (first approved 1997 by the FDA).
• Drug class: Platelet-reducing Agent.
• Mechanism of action: Phosphodiesterase 3 Inhibitors.
• Molecular targets: PDE3A and PDE2A (2 listed in DrugCentral).
• Indications: Essential thrombocythemia and Thrombocytosis in Myeloproliferative Disease.
• ATC code: L01XX35 (Other antineoplastic agents).
• Molecular formula: C10H7Cl2N3O; molecular weight 256.09 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (2)

• Essential thrombocythemia
• Thrombocytosis in Myeloproliferative Disease

Contraindications (11)

• Anemia
• Blood coagulation disorder
• Disease of liver
• Eosinophilic asthma
• Heart disease
• Hepatic failure
• High output heart failure
• Interstitial lung disease
• Interstitial pneumonia
• Kidney disease
• Thrombocytopenic disorder

Mechanism & targets

• Mechanism of action (MoA): Phosphodiesterase 3 Inhibitors
• Established pharmacologic class: Platelet-reducing Agent

Molecular targets (2)

Target	Gene	Action	Activity
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	PDE3A	inhibitor	IC50 7.27
cGMP-dependent 3',5'-cyclic phosphodiesterase	PDE2A	unknown	IC50 4.47

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2004-11-15	EMA	—	SHIRE PHARMACEUTICALS IRELAND LIMITED	Yes
1997-03-14	FDA	—	SHIRE LLC	Yes

ATC classification

ATC code	Therapeutic hierarchy
L01XX35	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › OTHER ANTINEOPLASTIC AGENTS › Other antineoplastic agents

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Platelet count increased	218.3
Myelofibrosis	212.7
Thrombocytosis	98.5
Angiodermatitis	86.6
Skin ulcer	66.7
Splenomegaly	65.0
Myeloproliferative neoplasm	57.5
Anaemia	55.9
Prinzmetal angina	54.5
Acute myocardial infarction	53.2
Bone marrow reticulin fibrosis	48.3
Cerebral infarction	44.3

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Anagrelide is on its molecule page.

• Molecular formula: C₁₀H₇Cl₂N₃O
• Molecular weight: 256.09 g/mol
• CAS number: —
• InChIKey: OTBXOEAOVRKTNQ-UHFFFAOYSA-N
• PubChem CID: 135409400

ClC1=CC=C2N=C3NC(=O)CN3CC2=C1Cl

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Anagrelide used for?

DrugCentral lists the following indications for Anagrelide: Essential thrombocythemia and Thrombocytosis in Myeloproliferative Disease.

How does Anagrelide work?

Anagrelide is classified as Phosphodiesterase 3 Inhibitors; its molecular targets in DrugCentral include PDE3A (inhibitor) and PDE2A.

When was Anagrelide first approved?

Anagrelide was first approved by the FDA in 1997.

What drug class does Anagrelide belong to?

Anagrelide is in the Platelet-reducing Agent class.

What is the chemical formula of Anagrelide?

Anagrelide has the molecular formula C10H7Cl2N3O and a molecular weight of 256.09 g/mol.

Sources

• DrugCentral drug card 209 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200759 — compound record and bioactivity
• PubChem CID 135409400 — chemical identifiers
• DrugBank DB00261 — drug record
• FDA UNII K9X45X0051 — substance identity
• DailyMed: FDA labels for Anagrelide — current prescribing information (label search)
• UniProt Q14432 (PDE3A) — target protein
• UniProt O00408 (PDE2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.